Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	21.41	6.28	5.85	5.5	4.77
Research & Development	100.64	1.01	4.75	13.83	4.99
Total Operating Expenses	122.05	7.3	10.6	19.34	9.77
Operating Income	-122.05	-7.3	-10.6	-19.34	-9.77
Interest Income	16.63	1.96	0.68	0.01	0.03
Interest Expense	-	-	-	-	-0.01
Other Non-Operating Income (Expense)	-0.01	-	-0.01	-	-
Total Non-Operating Income (Expense)	16.62	1.96	0.67	0.01	0.02
Pretax Income	-105.43	-5.34	-9.93	-19.32	-9.75
Provision for Income Taxes	-	-	-	-	-0.01
Net Income	-105.43	-5.34	-9.93	-19.32	-9.74
Net Income to Common	-105.43	-5.34	-9.93	-19.32	-9.74
Shares Outstanding (Basic)	46	1	1	1	0
Shares Outstanding (Diluted)	46	1	1	1	0
Shares Change (YoY)	3696.99%	0.04%	3.64%	195.18%	256.50%
EPS (Basic)	-1.85	-4.44	-8.28	-16.68	-24.84
EPS (Diluted)	-1.85	-4.44	-8.28	-16.68	-24.84
Shares Outstanding	48.72	1.21	14.41	14.41	9.55
Free Cash Flow	-88.42	-5.01	-10.91	-18.81	-7.74
Free Cash Flow Per Share	-1.94	-4.17	-9.09	-16.23	-19.73
EBITDA	-121.97	-7.28	-10.58	-19.32	-9.76
EBIT	-122.05	-7.3	-10.6	-19.34	-9.77
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.09%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q